ClinicalTrials.gg
RecruitingNCT05970016Updated Mar 21, 2025

A Phase I/II Clinical Study in Patients with Advanced Solid Tumor.

A Phase 1/2 interventional study of TCC1727 tablet(1) and TCC1727 tablet(2) in Patients with Advanced Solid Tumors, sponsored by Beijing Tide Pharmaceutical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-03-21.

Sponsored by Beijing Tide Pharmaceutical Co., Ltd (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
56
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a 2-part, phase I/II, open-label, multicenter study designed to evaluate the safety, PK, PD and preliminary efficacy of TCC1727 tablets administered orally QD.

Read the detailed description

The study will be divided into two stages: the first stage is a phase I dose finding study in patients with advanced solid tumors; the second stage is a phase II cohort expansion study.

02

Conditions studied

  • Patients with Advanced Solid Tumors
03

In context

Lead sponsor

Beijing Tide Pharmaceutical Co., Ltd is the lead sponsor of 14 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects who have provided voluntary for participation in the study and to follow the protocol requirements
  2. Male or female subjects 18-70 years of age
  3. Subjects with or cytologically confirmed malignant advanced solid tumors who have progressed on (or have not been able to tolerate) standard therapy or for whom no suitable effective standard therapy exists

    1. For Phase I, all tumor types will be enrolled
    2. For Phase II, Patients with DDR defects detection at central laboratory will be enrolled
  4. Subject with at least one according to criteria (version 1.1) for solid tumors will be allowed to include in phase II (if there is no measurable lesion but there are assessable lesions then the subject will be allowed to be included after the judgment of the investigator in phase I only)
  5. (ECOG) performance status of 0 or 1
  6. Subjects with of ≥12 weeks
  7. Subjects 12-lead evaluation of level using Fridericia formula (QTcF) \< 450 mse
  8. Subjects must have the following laboratory values:

    1. (ANC) ≥ 1.5 × 109/L;
    2. count (PLT) ≥ 100 × 109/L;
    3. (HB) ≥ 9.0 g/L;
    4. No blood transfusion or hematopoietic stimulating factor treatment within 14 days;
    5. total ≤ 1.5 times the (ULN);
    6. (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN (In case of liver , ALT and AST ≤ 5 × ULN);
    7. 24-hour or calculated (CrCl) ≥ 60 mL/min (according to Cockcroft-Gault formula)*, or the 24-hour creatinine clearance measured in urine is ≥ 50 mL/min, the patient will still be selected. *For CrCl value, the eligibility should be determined using the Cockcroft-Gault formula:

      • Male CrCl (mL/min) = body weight (kg) × (140 - age)/[72 × serum creatinine (mg/dL)]
      • Female CrCl (mL/min) = male CrCl × 0.85
    8. (INR) ≤ 1.5 × ULN, Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN;
  9. Women of agreed to use effective during the study treatment period and within 3 months after the end of the study treatment period.

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded from the study based on the following criteria:

  1. Imaging examination suggests intracranial , which requires local treatment (in case of asymptomatic or symptomatic requiring no local treatment based on the investigator's judgement, the subject can still be included), or currently taking hormone prior to inclusion, such as >10 mg prednisone (or equivalent) for intracerebral edema from brain metastases; subjects with meningeal carcinomatosis will be excluded regardless of their clinical stability
  2. History of previously received major surgery or surgical therapy for any cause within 4 weeks of the first dose; radiotherapy, chemotherapy, other clinical trial drugs or other anti-tumor treatment, within 5 half-lives or 3 weeks (whichever is shorter), prior administering the first dose of study drug on Day 1
  3. History of previous treatment with ATR inhibitors or other DDR related inhibitors (except poly ADP ribose polymerase enzyme (PARP) inhibitors)
  4. Subjects with a history of another primary other than:

    1. carcinomas in situ, (e.g., breast, cervix, and prostate)
    2. Locally excised non-melanoma skin cancer
    3. No evidence of disease from another primary cancer for two or more years and has not taken any anti-cancer treatment in two years. Exceptions are gonadotropin-releasing hormone (GnRH) therapy for prostate cancer and hormonal maintenance therapy for breast cancer.
  5. Previously received treatment with strong , CYP2C8 and P-gp inhibitors or strong CYP3A4, CYP2C8 and P-gp inducers within 14 days prior to the first medication
  6. Patients with AE due to previous anti-tumor treatment that has not recovered to ≤ grade 1 (except for alopecia, pigmentation and lymphopenia)
  7. Patients who are unable to swallow the tablets normally, or have abnormal gastrointestinal function that may affect the drug absorption, such as malabsorption syndrome or major resection of the stomach or bowels based on the judgment of the investigator
  8. Subjects with any severe and/or uncontrolled disease, including:

    1. Poor blood pressure control (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg)
    2. Myocardial infarction, arrhythmia (CTCAE grade 2 and above, also including ≥ Class II congestive heart failure (CHF) ( (NYHA) classification) (refer to Appendix-A)
    3. Active infection or fever of unknown origin ≥ 38.5℃ within 7 days prior to the first medication
    4. Active viral hepatitis; positive surface antigen and/or hepatitis B core antibody and measured HBV DNA value ≥ 500 IU/ml; positive antibody and measured HCV titer exceeding the ;
    5. Positive Treponema pallidum antibody;
    6. History of immunodeficiency, including positive antibody or other acquired or congenital immunodeficiency diseases, or history of organ transplant;
    7. Poor control of diabetes (fasting blood glucose (FBG) > 10 mmol/L);
    8. Liver disease such as decompensated liver disease
  9. Uncontrolled pleural effusion, pericardial effusion, or peritoneal effusion as per the investigator opinion
  10. Patients with hemorrhage symptoms or bleeding tendency within 3 months prior to the first study medication
  11. Known or to any drug or any of the components of product
  12. Any other clinically significant acute or chronic medical or psychiatric or any laboratory abnormality that may increase the risk associated with study drug administration or may interfere with the interpretation of study results
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    5mg treatment group

    Administered orally once a day (QD)

    Drug: TCC1727 tablet(1)

  • Experimental
    10mg treatment group

    Administered orally once a day (QD)

    Drug: TCC1727 tablet(1)

  • Experimental
    20mg treatment group

    Administered orally once a day (QD)

    Drug: TCC1727 tablet(1)

  • Experimental
    40mg treatment group

    Administered orally once a day (QD)

    Drug: TCC1727 tablet(1)

  • Experimental
    60mg treatment group

    Administered orally once a day (QD)

    Drug: TCC1727 tablet(1)

  • Experimental
    80mg treatment group

    Administered orally once a day (QD)

    Drug: TCC1727 tablet(1)

  • Experimental
    100mg treatment group

    Administered orally once a day (QD)

    Drug: TCC1727 tablet(1)

  • Experimental
    60mg BID treatment group

    Drug: TCC1727 tablet TCC1727 tablet will be administered orally twice a day (BID) every morning , and 21 days/cycle on an empty stomach.

    Drug: TCC1727 tablet(2)

  • Experimental
    90mg BID treatment group

    Drug: TCC1727 tablet TCC1727 tablet will be administered orally twice a day (BID) every morning, and 21 days/cycle on an empty stomach.

    Drug: TCC1727 tablet(2)

  • Experimental
    120mg BID treatment group

    Drug: TCC1727 tablet TCC1727 tablet will be administered orally twice a day (BID) every morning, and 21 days/cycle on an empty stomach.

    Drug: TCC1727 tablet(2)

  • Experimental
    160mg BID treatment group

    Drug: TCC1727 tablet TCC1727 tablet will be administered orally twice a day (BID) every morning, and 21 days/cycle on an empty stomach.

    Drug: TCC1727 tablet(2)

Interventions

  • DrugTCC1727 tablet(1)

    TCC1727 tablet will be administered orally once a day (QD) every morning for 3 days followed by discontinuation for 4 days, and 21 days/cycle on an empty stomach.

  • DrugTCC1727 tablet(2)

    Drug: TCC1727 tablet TCC1727 tablet will be administered orally twice a day (BID) every morning , and 21 days/cycle on an empty stomach.

06

What researchers measure

Primary outcomes

  1. Phase I: To determine dose-limiting toxicity (DLT) at each dose level and identify MTD and RP2D.

    Phase I: Dose Escalation To observe the tolerability and safety of TCC1727 tablets and determine the maximum-tolerated dose (MTD) and the recommended phase II dose (RP2D) of TCC1727 tablets when administered orally once a day (QD) in 21-day cycle in patients with advanced solid tumors.

    Time frame: 21 days

  2. Phase II: To evaluate the preliminary efficacy of TCC1727 tablets as measured by ORR in patients with advanced solid tumors with DNA damage response (DDR) defects

    Phase II: Cohort Expansion ORR according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1, 2009) for each tumor type. The overall response rate is defined as proportion of subjects who had the best overall response (BOR) of complete response (CR) or partial response (PR).

    Time frame: 6 months

Secondary outcomes

  1. Phase I: Dose Escalation To observe the preliminary efficacy of TCC1727 tablets as measured by overall response rate (ORR) in patients with advanced solid tumors.

    To evaluate the preliminary efficacy by objective response rate (ORR), disease control rate (DCR), duration of response (DOR), progression free survival (PFS) and overall survival (OS).

    Time frame: 6 months

  2. Phase I: To evaluate the pharmacokinetic (PK) of TCC1727 tablets in patients with advanced solid tumors

    Phase I: Dose Escalation Pharmacokinetic parameters: Tmax

    Time frame: 21 days

  3. Phase I:

    Phase I: Dose Escalation Pharmacokinetic parameters: Cmax

    Time frame: 21 days

  4. Phase I:

    Phase I: Dose Escalation Pharmacokinetic parameters: t1/2

    Time frame: 21 days

  5. Phase I:

    Phase I: Dose Escalation Pharmacokinetic parameters: AUC0-t,

    Time frame: 21 days

  6. Phase I:

    Phase I: Dose Escalation Pharmacokinetic parameters: Cmax,ss

    Time frame: 21 days

  7. Phase I:

    Phase I: Dose Escalation Pharmacokinetic parameters: AUCtau,ss,

    Time frame: 21 days

  8. Phase I:

    Phase I: Dose Escalation Pharmacokinetic parameters: Cmin,ss

    Time frame: 21 days

  9. Phase II: To evaluate the safety and tolerability of TCC1727 tablets in patients with advanced solid tumors with DDR defects

    Phase II: Cohort Expansion Assessment of all AEs, SAEs and TEAEs;

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2023 (actual). Primary completion is estimated for Jul 2025, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2023
First posted
Aug 1, 2023
StartActual
Aug 7, 2023
Primary completionEst.
Jul 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Mar 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05970016
Responsible party
Sponsor
First posted
Aug 1, 2023
Start date
Aug 7, 2023
Primary completion
Jul 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Mar 21, 2025

Study contacts

Lingying Wu, PHD
Contact
wulingying@csco.org.cn
86-01-87788996
Guangwen Yuan, PHD
Contact
william327@126.com
86-01-87788996

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion